CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Rpi Finance Trust	Common Stock	Common Stock Rpi Finance Trust	Capital Contributed in Excess of Par	Capital Contributed in Excess of Par Rpi Finance Trust	Treasury Stock	Treasury Stock Rpi Finance Trust	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income	Noncontrolling Interest	Convertible preferred stock	IPO	IPO Common Stock	IPO Capital Contributed in Excess of Par	Private placement Seattle Genetics, Inc., (“SGEN”)	Private placement Common Stock Seattle Genetics, Inc., (“SGEN”)	Private placement Capital Contributed in Excess of Par Seattle Genetics, Inc., (“SGEN”)	Market Offering	Market Offering Common Stock	Market Offering Capital Contributed in Excess of Par
Beginning balance (in shares) at Jun. 30, 2016			95,868,000									0
Beginning balance at Jun. 30, 2016	$ (57,528)		$ 958		$ 311,320		$ (458)		$ (368,505)	$ (132)	$ (711)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of preferred stock (in shares)												1,000,000
Issuance of preferred stock, net	121,782				121,772							$ 10
Issuance of common stock (in shares)														10,000,000			3,000,000
Issuance of common stock, net													$ 28,578	$ 100	$ 28,478	$ 14,700	$ 30	$ 14,670
Proceeds of public offering allocated to warrant liability	(6,966)				(6,966)											$ (14,670)		$ (14,670)
Exercise of stock options (in shares)			1,279,000
Exercise of stock options, net	4,290		$ 13		4,277
Stock based compensation (in shares)			198,000
Stock-based compensation	3,787		$ 2		3,785
Other comprehensive income (loss)	(171)									(171)
Net loss	(153,266)								(153,206)		(60)
Ending balance (in shares) at Jun. 30, 2017			110,345,000									1,000,000
Ending balance at Jun. 30, 2017	(59,464)		$ 1,103		462,666		(458)		(521,711)	(303)	(771)	$ 10
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reclassification of warrant liability to equity	190,369				190,369
Issuance of common stock (in shares)				4,373,000										13,225,000
Issuance of common stock, net		$ 67,784		$ 44		$ 67,740							299,467	$ 132	299,335
Exercise of common stock warrants (in shares)			18,206,000
Exercise of common stock warrants	78,226		$ 182		78,044
Exercise of stock options (in shares)			586,000
Exercise of stock options, net	2,261		$ 6		2,255
Conversion of preferred shares (in shares)			23,105,000									1,000,000
Conversion of preferred stock	0		$ 231		(221)							$ (10)
Issuance of common stock due to debt conversion (in shares)			16,800,000
Issuance of common stock due to debt conversion	92,475		$ 168		92,307
Stock based compensation (in shares)			331,000
Stock-based compensation	4,027		$ 3		4,024
Conversion of RSU's for tax withholding payments (in shares)			(170,000)
Conversion of RSU's for tax withholding payments	(1,522)		$ (1)		(1,521)
Other comprehensive income (loss)	(50)									(50)
Net loss	(273,887)								(273,837)		(50)
Ending balance (in shares) at Jun. 30, 2018			186,801,000									0
Ending balance at Jun. 30, 2018	399,686		$ 1,868		1,194,998		(458)		(795,548)	(353)	(821)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reclassification of warrant liability to equity	7,569				7,569
Exercise of common stock warrants (in shares)			450,000
Exercise of common stock warrants	1,688		$ 5		1,683
Exercise of stock options (in shares)			706,000
Exercise of stock options, net	$ 176		$ 7		2,619		(2,450)
Retirement of treasury stock (in shares)	(105,959)			(106,000)
Retirement of treasury stock		$ 0		$ (1)		$ (2,083)		$ 2,084
Issuance of common stock due to debt conversion (in shares)			2,568,000
Issuance of common stock due to debt conversion	$ 13,783		$ 26		13,757
Stock based compensation (in shares)			36,000
Stock-based compensation	886				886
Conversion of RSU's for tax withholding payments (in shares)			(9,000)
Conversion of RSU's for tax withholding payments	(192)				(192)
Other comprehensive income (loss)	2									2
Net loss	(157,749)								(157,668)		(81)
Ending balance (in shares) at Dec. 31, 2018			190,446,000									0
Ending balance at Dec. 31, 2018	265,849		$ 1,905		1,219,237		(824)		(953,216)	(351)	(902)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)														16,429,000						4,432,000
Issuance of common stock, net													$ 273,031	$ 164	$ 272,867				$ 71,597	$ 44	$ 71,553
Exercise of stock options (in shares)			1,207,000
Exercise of stock options, net	2,553		$ 12		3,812		(1,271)
Stock based compensation (in shares)			15,000
Stock-based compensation	11,736				11,736
Other comprehensive income (loss)	(217)									(217)
Net loss	(357,319)								(357,190)		(129)
Ending balance (in shares) at Dec. 31, 2019			212,529,000									0
Ending balance at Dec. 31, 2019	$ 267,230		$ 2,125		$ 1,579,205		$ (2,095)		$ (1,310,406)	$ (568)	$ (1,031)	$ 0